Curia Global Inc., a contract research, development and manufacturing organization, has refinanced its senior secured credit facilities.

The transaction provides Curia with additional capital and extends the maturities of its secured credit facilities, positioning the business for sustained growth. This enables the company to capitalize on promising market opportunities in the drug development and manufacturing sectors. Moreover, it aligns with the company’s mission of partnering with biopharmaceutical customers to bring life-changing therapies to market.

“The refinancing demonstrates the confidence our lenders and investors have in Curia,” said Philip Macnabb, CEO. “The new credit facility will enable us to continue investing in key growth projects that enhance our differentiated capabilities and deliver greater value for our customers.”

Recent organic growth initiatives include a significant investment in Curia’s Rensselaer, New York, facility to expand commercial manufacturing capacity for complex active pharmaceutical ingredients. Curia has also made a significant investment in new sterile fill-finish capabilities at the company’s facility in Albuquerque, New Mexico, with further plans to expand fill-finish capabilities at its Glasgow, UK facility that will more than double current GMP batch size.